- Home
- BFRI vs PHIO Comparison
BFRI vs PHIO Comparison
Compare BFRI & PHIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | BFRI | PHIO |
|---|---|---|
| Founded | 1997 | 2011 |
| Country | United States | United States |
| Employees | 93 | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.6M | 12.3M |
| IPO Year | N/A | 2011 |
Fundamental Metrics
Financial Performance| Metric | BFRI | PHIO |
|---|---|---|
| Price | $0.90 | $1.04 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 3 |
| Target Price | $2.75 | ★ $10.67 |
| AVG Volume (30 Days) | 492.6K | ★ 7.1M |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $11.37 | N/A |
| Revenue Next Year | $10.96 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.54 | $0.81 |
| 52 Week High | $1.18 | $4.19 |
Technical Indicators
Market Signals| Indicator | BFRI | PHIO |
|---|---|---|
| Relative Strength Index (RSI) | 52.26 | 46.44 |
| Support Level | $0.81 | $0.97 |
| Resistance Level | $0.91 | $1.21 |
| Average True Range (ATR) | 0.08 | 0.18 |
| MACD | 0.01 | -0.01 |
| Stochastic Oscillator | 73.91 | 6.32 |
Price Performance
Historical ComparisonAbout BFRI Biofrontera Inc.
Biofrontera Inc is a United States-based biopharmaceutical company commercializing a portfolio of pharmaceutical products for the treatment of dermatological conditions with a focus on photodynamic therapy. The Company's licensed products, which include Ameluz as well as the BF-RhodoLED and RhodoLED XL lamps (together, the RhodoLED Lamps), are used for the treatment of actinic keratoses (AKs), which are pre-cancerous skin lesions.
About PHIO Phio Pharmaceuticals Corp.
Phio Pharmaceuticals Corp is a clinical-stage biotechnology company whose proprietary INTASYL self-delivering RNAi technology platform is designed to make immune cells more effective in killing tumor cells. The Company is developing therapeutics that are designed to leverage INTASYL to precisely target specific proteins that reduce the body's ability to fight cancer, without the need for specialized formulations or drug delivery systems.